Brought to you by:
![Vascular Specialist [LIVE]](https://vascularspecialistonline.com/wp-content/uploads/2026/08/vascular_specialist_logo_forwebsite_new.png){kind=logo}
ROADSTER 3 provides key evidence that ‘goes beyond registry data’ on TCAR-related stroke rates
Thirty-day results from the ROADSTER 3 study have demonstrated that transcarotid artery revascularization (TCAR) is a safe and effective approach in patients who are deemed to be standard risk for experiencing adverse events related to carotid endarterectomy (CEA). These findings…
Silk Road celebrates milestone of 100,000 TCAR procedures
Silk Road Medical has announced the milestone of more than 100,000 transcarotid artery revascularisation (TCAR) procedures having been performed to date. “A growing number of patients come to us looking for a solution that is minimally invasive and requires less…
Boston Scientific announces agreement to acquire Silk Road Medical
Boston Scientific has announced that it has entered into a definitive agreement to acquire Silk Road Medical, a medical device company involved in producing products to be deployed during transcarotid artery revascularisation (TCAR). The purchase price is US$27.50 per share,…
TCAR has ‘tremendous appeal’ as alternative to transfemoral carotid artery stenting
This video is sponsored by Silk Road Medical. Richard Powell, MD, from Lebanon, New Hampshire, talks to Vascular Specialist at the Society for Vascular Surgery’s Vascular Annual Meeting (SVS VAM; June 15–18) in Boston about his initial interest in the…